Related references
Note: Only part of the references are listed.Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
Martin F. Kaiser et al.
BLOOD (2013)
Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis
Christoph J. Heuck et al.
JOURNAL OF IMMUNOLOGY (2013)
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
Metin Karahoca et al.
CLINICAL EPIGENETICS (2013)
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
Ken Maes et al.
Cancers (2013)
Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jerome Moreaux et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Brian A. Walker et al.
BLOOD (2011)
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
Jerome Moreaux et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Dirk Hose et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The potential role of epigenetic therapy in multiple myeloma
Emma M. Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Paul W. Hollenbach et al.
PLOS ONE (2010)
Share Paper
